Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Axios on your phone

Get breaking news and scoops on the go with the Axios app.

Download for free.

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Gilead has not yet named a price for remdesivir yet. Photo: Liu Guanguan/China News Service via Getty Images

A fair price for Gilead's coronavirus drug, remdesivir, likely should not exceed $2,800 for a course of treatment, according to updated estimates from experts at the Institute for Clinical and Economic Review.

The bottom line: Gilead hasn't released a final price for remdesivir yet, and it could set the bar for other coronavirus treatments that come after it.

Details: ICER — which conducts cost-effectiveness analyses on drugs and other medical treatments — originally released remdesivir price estimates in May, but revised its figures as more information has come out:

  • $10 per treatment: Same low-end estimate assumes recovery of basic costs plus a small margin.
  • $310 per treatment: This price reflects the drug's current clinical benefit, which reduces hospitalization time but does not reduce the chance of death. (If the drug shows a mortality benefit later, this could go up to $5,000.)
  • $600 per treatment: Roughly what generic drug companies are charging for remdesivir overseas.
  • $1,600 per treatment: If Gilead tried to recoup new research costs.
  • $2,800 per treatment: This assumes dexamethasone becomes the new standard for hospitalized coronavirus patients, and "therefore the overall lives and life years saved with remdesivir are lower," ICER said.

Go deeper

Mark Meadows: Trump's blood oxygen level "dropped rapidly," but he's doing well

White House Chief of Staff Mark Meadows speaks to reporters about President Trump's positive coronavirus test outside the West Wing of the White House on Friday. Photo: Drew Angerer/Getty Images

White House Chief of Staff Mark Meadows told Fox News Saturday night that officials were "concerned" about President Trump's condition after he was diagnosed with the coronavirus, but he's now "doing well."

Why it matters: There have been conflicting reports from the White House on Trump's condition. Meadows' remarks come after White House physician Sean Conley said Saturday that Trump "remains fever-free and off supplemental oxygen," but that the president is "not yet out of the woods."

Updated Nov 9, 2020 - Health

23 states set single-day coronavirus case records last week

Data: Compiled by Axios; Map: Danielle Alberti/Axios

23 states set new highs last week for coronavirus infections recorded in a single day, according to the COVID Tracking Project (CTP) and state health departments. 15 states surpassed records from the previous week.

Why it matters: More states across the country are handling record-high caseloads than this summer.

Updated Oct 25, 2020 - Politics & Policy

Trumpworld coronavirus tracker

Photo: Saul Loeb/AFP via Getty Images

An outbreak of COVID-19 has struck the White House — including the president himself — just weeks before the 2020 election.

Why it matters: If the president can get infected, anyone can. And the scramble to figure out the scope of this outbreak is a high-profile, high-stakes microcosm of America's larger failures to contain the virus and to stand up a contact-tracing system that can respond to new cases before they have a chance to become outbreaks.